“Why Are Girls Getting Their Periods So Early? - Momlogic.com” plus 4 more |
- Why Are Girls Getting Their Periods So Early? - Momlogic.com
- Plan adds flexibility to graduation credits - Argus Leader
- Enzo Biochem Appoints Dr. Mohan Chellani, 15-Year Industry Veteran ... - MSN Money
- GeneGo Licenses MetaCore to Proteostasis Therapeutics - Phramalive.com
- Enzo Biochem to Present at Rodman & Renshaw Annual Global Investment ... - Genetic Engineering News
| Why Are Girls Getting Their Periods So Early? - Momlogic.com Posted: 08 Sep 2009 08:35 AM PDT It has as much to do with your divorce as with hormones in the food. Dr. Wendy Walsh: No doubt about it, girls are getting their periods earlier and earlier -- and this has been going on for decades. I was just shy of my fifteenth birthday when I started menstruating back in the 1970s. My daughter was only ten when she got her first period this year. Since she wore pull-up diapers at night for many years until her bladder matured, I feel like I had only a brief reprieve between buying diapers and pads! While the Internet is crawling with posters that quickly point to hormones used to increase meat, chicken, and dairy production as the basis for this phenomenon, there is a far more complicated answer -- part of which might make you feel a bit uncomfortable. Let's start with eating in general. Kids eat too much of everything, not just hormone-laced food. Carrying excess body fat raises estrogen levels that can lead to early puberty. Keeping girls active with low body fat levels is one way to delay this process. I'll put money on the fact that a high-carb, high-fat, vegetarian diet that causes one to be overweight is probably more likely to produce early puberty than one that includes bovine estrogen in hamburgers. Next, look no further than your neighborhood bus stop or the ads on TV for another puberty stimulus. We live in a highly sexualized culture. There are images everywhere of youthful, nubile models and actors in highly suggestive poses. When our brains take in this visual stimulation, our bodies have a reaction. If someone cuts a lemon across a room, you salivate. If someone assaults you with sexual images, you have a different kind of reaction. For children and tweens, the sexual images in our media function as a signal to the pituitary gland that they have left the nest and are out in the field ready to reproduce. So, their body steps up its natural process. And speaking of sexual signals, some experts think early puberty has less to do with food hormones and more to do with pheromones and the changing family structure. For thousands of years, girls lived in nuclear families. The smell of males with shared biology -- fathers and brothers -- functioned to suppress ovulation. Yes, the scent of a smelly brother's B.O. was enough to inform a girl's biology that she was still in the nest and not ready to reproduce. But today families have changed. Young girls are exposed to the male pheromones of stepfathers and stepbrothers, and even mommy's boyfriends. Some experts in human biology believe this has changed the game for girls' bodies. It's a complicated question with complicated answers. There are probably many more factors that contribute to the trend of early puberty. It's also natural. Each generation gets bigger, sooner. But when moms are helping their 9-year-olds insert tampons so they can be on the swim team, it does feel terribly premature. |
| Plan adds flexibility to graduation credits - Argus Leader Posted: 08 Sep 2009 08:28 AM PDT A new set of rules being recommended to the South Dakota Board of Education would award classroom credit to football players and marching band members, let students graduate without taking any health or gym classes, and make geometry and biology classes mandatory. Summer work group members who created the proposals say they want to give students the flexibility to pursue what interests them. But the plans are drawing criticism from health advocates and higher-education officials. This is the fourth year of a system that offers three pathways to graduation. For most students, 17 of the 22 credits needed for graduation are mandatory classes. A student who takes advantage of all proposed changes could drop the requirements to 13.5 credits. "The hope is that it will create flexibility," Education Secretary Tom Oster said, adding that the three pathways created a lot of confusion. Lawmakers eliminated the standard or basic pathway last session, so the work group's task was to create a new set of bare minimums. Local school boards may set their bars higher. Compared to the basic pathway, the proposed rules are more stringent: Geometry would be mandatory, and students would have to take three years of science instead of two, including biology and a physical science. Still, the group's higher-education representative sees the proposal as the "watering down of standards." The advanced pathway, which most students take, calls for algebra II and chemistry or physics; the proposed rules do not. Sam Gingerich, chief academic officer for the South Dakota Board of Regents, said the advanced pathway aligns with expectations for high school graduates entering the work force and college. In recent years, fewer South Dakota students have gone to college needing remedial coursework, he said, and employers here have found high school graduates with improved math and science skills. "It is our concern that stepping back from this may be sending the wrong message nationally," Gingerich said. More electives would be allowedWashington High School Principal Jamie Nold, who also participated in the work group, said the proposed changes would not affect higher-level students. College-bound students still will understand what classes they are expected to take, he said. |
| Enzo Biochem Appoints Dr. Mohan Chellani, 15-Year Industry Veteran ... - MSN Money Posted: 08 Sep 2009 07:02 AM PDT Enzo Biochem, Inc. ENZ today announced the appointment of Mohan Chellani, Ph.D., formerly a senior manager with Quest Diagnostics, as Vice President of Scientific Affairs at its Enzo Clinical Labs subsidiary. He will oversee all aspects of the Labs' Molecular Diagnostic's strategy and implementation, including serving as a key interface with Enzo Life Sciences, another Enzo subsidiary. Enzo Biochem is a biotechnology company specializing in gene identification and genetic and immune regulation technologies for diagnostic and therapeutic applications and laboratory services. "Dr. Chellani adds outstanding experience that will greatly benefit us," said Dr. Kevin Krenitsky, President, Enzo Clinical Labs. "We are on target at the Labs to not only capitalize on our progress in quality improvement, but also to further our growth strategy to broaden our capabilities in molecular diagnostics and other new dynamic, esoteric tests in line with today's advances in medicine. Dr. Chellani is an important addition to our team, and we are pleased to have him join us." Dr. Chellani, with over 15 years experience in the clinical laboratory business, most recently was Head of Science and Innovation Portfolio Development at Quest Diagnostics. Among his responsibilities were growing Quest's esoteric testing business, introducing assays and regionalized tests, and directing product development collaborations with academic and industry partners. Previously, Dr. Chellani served as a Senior Scientist in molecular immunology at Abbott Laboratories, head of Molecular Biology at PerSeptive Diagnostics, director of business development for biocalorimetric assays at MicroCal Inc., and Program Director, Biomics, at Perkin Elmer Life Sciences. About Enzo Enzo Biochem is engaged in the research, development, manufacture and licensing of innovative health care products and technologies based on molecular biology and genetic engineering techniques, and in providing diagnostic services to the medical community. Enzo's Life Sciences division develops, produces and markets proprietary labeling and detection products for gene sequencing, genetic analysis and immunological research among others. Its catalog of over 40,000 products serves the molecular biology, drug discovery and pathology research markets. The Company's therapeutic division is in various stages of clinical evaluation of its proprietary immune regulation medicines for uveitis and Crohn's disease and conducts pre-clinical research on several candidate compounds aimed at producing new mineral and organic bone, including technology that could provide therapy for osteoporosis and fractures, among other applications. Enzo's Clinical Labs division provides routine and esoteric reference laboratory services for physicians in the New York Metropolitan and New Jersey areas. Underpinning the Company's technology and operations is an extensive intellectual property estate in which Enzo owns or licenses over 230 patents worldwide, and has pending applications for over 200 more. For more information visit our website www.enzo.com. Except for historical information, the matters discussed in this news release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this press release. Enzo Biochem, Inc. Copyright 2009 Business Wire |
| GeneGo Licenses MetaCore to Proteostasis Therapeutics - Phramalive.com Posted: 08 Sep 2009 05:00 AM PDT
ST. JOSEPH, Mich., Sept. 8 /PRNewswire/ -- GeneGo, Inc., the leading systems biology tools company, announced today that Proteostasis Therapeutics has licensed its data mining and analysis platform, MetaCore. Proteostasis Therapeutics is the first company dedicated to the discovery of novel small molecule therapeutics based upon understanding the body's Proteostasis Network. The Proteostasis Network maintains the body's natural balance of proteins to protect us from numerous diseases. Deficiencies of the Proteostasis Network can lead to a wide spectrum of diseases, such as emphysema, type II diabetes, Alzheimer's Disease and Huntington's Disease. GeneGo's MetaCore is developing pathway reconstruction maps for a number of disease categories, including neurodegenerative disorders. Disease-specific pathway maps and models can be used as analytical tools to help advance our understanding of the diseases, their mechanisms and processes to help find cures faster. "We are very pleased to add Proteostasis as a new customer as we work towards delivering our unique disease specific platforms," said Julie Bryant, GeneGo's VP of Business development. "Understanding and capturing disease pathways is one of our top development priorities, and we are glad to see it appreciated by drug discovery companies." "Proteostasis Therapeutics is building a proprietary platform to rapidly translate the emerging knowledge of how the Proteostasis Network functions to discover novel small molecules, and GeneGo's MetaCore integrated software suite is a valuable tool in these efforts," said Hui Ge, Ph.D., Head of Systems Biology at Proteostasis Therapeutics. "We are pleased with GeneGo's comprehensive curated database of protein interactions, which enables us to rapidly use this information in our Proteostasis Network characterization efforts." About GeneGo, Inc. GeneGo, Inc. develops systems biology technology such as compound based pathway analysis, cheminformatics & bioinformatics software for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 5.4(TM), assists pharmaceutical scientists in the areas of target selection and validation, data mining in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 5.4(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore. For more information, please visit the company's web site at www.genego.com. Source: GeneGo, Inc. CONTACT: Julie Bryant, VP Business Development and Marketing of GeneGo, Web Site: http://www.genego.com/
|
| Enzo Biochem to Present at Rodman & Renshaw Annual Global Investment ... - Genetic Engineering News Posted: 08 Sep 2009 05:58 AM PDT CAREER CENTERWEBINARS
ADVERTISEMENT 
PODCASTS
MOST POPULARADVERTISEMENT |
Listen
Save
Comment
View All
| You are subscribed to email updates from Biology - Bing News To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
| Google Inc., 20 West Kinzie, Chicago IL USA 60610 | |
0 comments:
Post a Comment